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The use of the Zn-chelate of diethylenetriaminepentaacetate (DTPA)
instead of Ca-DTPA for removal of internaIly-deposited radionuclides has been
suggested (Catsch 1968, Catsch, Lö and Chambault 1964). This recom-
mendation is based on the fact that Zn-DTPA has a markedly lower toxicity
than Ca-DTPA (Catsch 1964, Catsch and Wedelstaedt 1960, Seide11970, Smith
1970, Weber 1969), but is only slightly less effective in mobilizing 91y and
I44Ce from the body (Catsch et al. 1964). Meanwhile, both chelates were found
to be equally effective in removing 147pm (Smith 1970), whereas the influence
Ca-DTPA on the excretion of 239PU seems to surpass that of the Zn-chelate
(Smith 1966). In the latter study, chelate treatment was initiated 1 hour after
injectioh of 239PU; the main objective of Zn-DTPA, however, is the delayed
treatment situation (Catsch 1968). In view of the great importance of 239PU, a
reinvestigation was advisable.
Fernale albino rats averaging 190 g in weight were injected intravenously
with 0·2 fLCi monomeric 239pu(IY) (0,25 ml., pR 8,5). Monomeric Pu was
prepared according to Taylor (personal communication) by diluting the stock
solution of PU(N03)2 with sodium citrate and filtration through millipore filter
(pore diameter 25 nm) before injection. Na3[Ca-DTPA] and Na3[Zn-DTPA],
respectively, were injected intraperitoneally on the 6th, 8th and 11th day; the
dosage equalled 1 mmol x kg-I x d-I (2 ml., pR 7·4). The o-activity of tissue
samples was assayed by liquid scintillation counting (Seidel and Volf, in press).
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Control Control Ca-DTPA Zn-DTPA
(0-9 per cent NaCI)
6th day 13th day 13th day 13th day
Liver 14-6 ±0'88 7-15 ±0'71 1'44 ±0'07 1-64 ±0'09
Spleen 0-24 ±0'02 0·32 ±0'02 0-16 ±0'01 0·18 ±0,01
Kidneys 1-04 ±0'04 0'74 ±0'05 0'45 ±0-04 0·36 ±0-02
Lung 0·14 z OOt 0-12 ±0'01 0'047 ± 0'003 0·054 ±0'005
Thyroid 0-22 ±0·003 0·016 ±0'0005 0-009 ± 0·001 0·008 ±0'001
Adrenals 0·012 ± 0'001 0'013 ± 0·001 0-006 ± 0-001 0·0062 ± 0-0003
I Ovaries 0·017 ± 0'001 0·016 ±0'002 0'010 ± 0-001 0-009 ±0'001
Skeleton 62·0 ± 1'09 56'5 ±0'54 41'5 ±2'20 40·9 ±0'79
239Pu-content of the organs (percentage of 239Pu_dose).
Means ± S.E. n = number of animals.
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As can be seen from the table, both chelates show virtually equal efficacy
in lowering the 239Pu-content of the organs. This is in keeping with recent
results obtained by Smith (personal communication) with 238PU. The favour-
able result of our study prompted us to start a more detailed investigation, which
will be concerned with the action of Zn-DTPA on monomeric and polymeric
239PU as influenced by treatment schedule.
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